Literature DB >> 21031587

Intractable vomiting as the initial presentation of neuromyelitis optica.

Metha Apiwattanakul1, Bogdan F Popescu, Marcelo Matiello, Brian G Weinshenker, Claudia F Lucchinetti, Vanda A Lennon, Andrew McKeon, Adam F Carpenter, Gary M Miller, Sean J Pittock.   

Abstract

We report 12 aquaporin-4 antibody-positive patients (12% of seropositive Mayo Clinic patients identified since 2005) whose initial presenting symptom of neuromyelitis optica was intractable vomiting. The initial evaluation in 75% was gastroenterologic. Vomiting lasted a median of 4 weeks (range, 2 days-80 weeks). Optic neuritis or transverse myelitis developed after vomiting onset in 11 patients (median interval, 11 weeks; range, 1-156). At last evaluation (median, 48 months after vomiting onset), 7 patients fulfilled neuromyelitis optica diagnostic criteria. Our clinical, pathologic and neuroimaging observations suggest the aquaporin-4-rich area postrema may be a first point of attack in neuromyelitis optica.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21031587     DOI: 10.1002/ana.22121

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  62 in total

1.  Syndrome of inappropriate antidiuresis may herald or accompany neuromyelitis optica.

Authors:  R Iorio; C F Lucchinetti; V A Lennon; C Costanzi; S Hinson; B G Weinshenker; S J Pittock
Journal:  Neurology       Date:  2011-10-12       Impact factor: 9.910

Review 2.  Aquaporin 4 and neuromyelitis optica.

Authors:  Marios C Papadopoulos; A S Verkman
Journal:  Lancet Neurol       Date:  2012-05-16       Impact factor: 44.182

Review 3.  [From neuromyelitis optica to neuromyelitis optica spectrum disorder: from clinical syndrome to diagnistic classification].

Authors:  Orhan Aktas; Tania Kümpfel
Journal:  Nervenarzt       Date:  2021-03-16       Impact factor: 1.214

4.  Evolution of longitudinally extensive transverse myelitis in an aquaporin-4 IgG-positive patient.

Authors:  Nasrin Asgari; Hanne Pernille Bro Skejoe; Vanda A Lennon
Journal:  Neurology       Date:  2013-07-02       Impact factor: 9.910

Review 5.  Common and Rare Manifestations of Neuromyelitis Optica Spectrum Disorder.

Authors:  Dominique Rosales; Ilya Kister
Journal:  Curr Allergy Asthma Rep       Date:  2016-06       Impact factor: 4.806

Review 6.  Neuromyelitis optica spectrum disorders.

Authors:  Eoin P Flanagan; Brian G Weinshenker
Journal:  Curr Neurol Neurosci Rep       Date:  2014-09       Impact factor: 5.081

7.  Racial differences in neuromyelitis optica spectrum disorder.

Authors:  Su-Hyun Kim; Maureen A Mealy; Michael Levy; Felix Schmidt; Klemens Ruprecht; Friedemann Paul; Marius Ringelstein; Orhan Aktas; Hans-Peter Hartung; Nasrin Asgari; Jessica Li Tsz-Ching; Sasitorn Siritho; Naraporn Prayoonwiwat; Hyun-June Shin; Jae-Won Hyun; Mira Han; Maria Isabel Leite; Jacqueline Palace; Ho Jin Kim
Journal:  Neurology       Date:  2018-10-26       Impact factor: 9.910

8.  The history of neuromyelitis optica.

Authors:  Sven Jarius; Brigitte Wildemann
Journal:  J Neuroinflammation       Date:  2013-01-15       Impact factor: 8.322

Review 9.  Finding NMO: The Evolving Diagnostic Criteria of Neuromyelitis Optica.

Authors:  Jeffrey L Bennett
Journal:  J Neuroophthalmol       Date:  2016-09       Impact factor: 3.042

Review 10.  What do we know about brain contrast enhancement patterns in neuromyelitis optica?

Authors:  Yeliz Pekcevik; Gunes Orman; In Ho Lee; Maureen A Mealy; Michael Levy; Izlem Izbudak
Journal:  Clin Imaging       Date:  2015-07-26       Impact factor: 1.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.